Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study
- 1 May 2001
- journal article
- case report
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 18 (3) , 187-192
- https://doi.org/10.1177/104990910101800310
Abstract
Psychostimulants such as methylphenidate are used for fatigue in cancer patients. We report a prospective, open-label, pilot study of the successful use of methylphenidate to treat fatigue in nine of 11 consecutive patients with advanced cancer. Seven had received radiation or chemotherapy, a median of three weeks (range from one to 30 weeks) prior to methylphenidate. A rapid onset of benefit was noted, even in the presence of mild anemia. Sedation and pain also improved in some. Only one patient had side effects severe enough to stop the medication.Keywords
This publication has 25 references indexed in Scilit:
- Short communicationJournal of Pain and Symptom Management, 1998
- Phase I Study Combining Tumor Necrosis Factor with Interferon-α and Interleukin-2American Journal of Clinical Oncology, 1997
- The Effects of Amantadine and Pemoline on Cognitive Functioning in Multiple SclerosisArchives of Neurology, 1996
- Fatigue therapy in multiple sclerosisNeurology, 1995
- Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatmentThe Journal of Neuropsychiatry and Clinical Neurosciences, 1995
- Neurobehavioral functioning and quality of life in patients treated for cancer of the central nervous systemCurrent Opinion in Oncology, 1995
- Erythropoietin for anaemia in cancer patientsEuropean Journal Of Cancer, 1993
- FatigueSeminars in Oncology Nursing, 1987
- A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple SclerosisCanadian Journal of Neurological Sciences, 1987
- Amantadine Therapy for Fatigue in Multiple SclerosisCanadian Journal of Neurological Sciences, 1985